Christof Vulsteke, MD, PhD, discusses results from the KEYNOTE-905 trial, evaluating perioperative EV/pembrolizumab in cisplatin-ineligible MIBC.
Christof Vulsteke, MD, PhD
Advertisement
Articles by Christof Vulsteke, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
MRI, myths, and precision: Stacy Loeb, MD, discusses modern prostate cancer screening
2
Dual targeting of PAM and AR pathways yields encouraging results in mCRPC
3
Health Canada approves testosterone undecanoate for hypogonadism
4
Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer
5
